TY - JOUR
T1 - Erratum
T2 - A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation (Clinical Cancer Research (2021) 27 (6366–6375) DOI: 10.1158/1078-0432.CCR-20-4185)
AU - Atrafi, Florence
AU - Boix, Oliver
AU - Subbiah, Vivek
AU - Diamond, Jennifer R.
AU - Chawla, Sant P.
AU - Tolcher, Anthony W.
AU - LoRusso, Patricia M.
AU - Eder, Joseph P.
AU - Gutierrez, Martin
AU - Sankhala, Kumar
AU - Rajagopalan, Prabhu
AU - Genvresse, Isabelle
AU - Langer, Simon
AU - Mathijssen, Ron H.J.
AU - Verweij, Jaap
AU - Bruns, Ingmar
AU - Lolkema, Martijn P.
N1 - Publisher Copyright:
© 2022 American Association for Cancer Research.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - In the original version of this article (1), errors exist in Tables 2, 3, and 4 and in the Results section. In Table 2, the bioavailability factor was listed for the oral solution instead of the liquid capsule formulation, which has a lower bioavailability of 38%, and thus the bioavailability factor in footnote "a"should list 2.6 instead of 2.7; also in Table 2, all five 90% credible interval values are for the oral solution instead of the liquid capsule formulation and should have been adjusted accordingly. In the Results section and in Table 3's footnote "a", the bioavailability of liquid capsule formation should be 38% instead of -31%. In Table 4, the 40% value for the Median MTD in mg for rCRM-20 should be 7.4 instead of 53.2. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.
AB - In the original version of this article (1), errors exist in Tables 2, 3, and 4 and in the Results section. In Table 2, the bioavailability factor was listed for the oral solution instead of the liquid capsule formulation, which has a lower bioavailability of 38%, and thus the bioavailability factor in footnote "a"should list 2.6 instead of 2.7; also in Table 2, all five 90% credible interval values are for the oral solution instead of the liquid capsule formulation and should have been adjusted accordingly. In the Results section and in Table 3's footnote "a", the bioavailability of liquid capsule formation should be 38% instead of -31%. In Table 4, the 40% value for the Median MTD in mg for rCRM-20 should be 7.4 instead of 53.2. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret the errors.
UR - http://www.scopus.com/inward/record.url?scp=85133220294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133220294&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-22-1792
DO - 10.1158/1078-0432.CCR-22-1792
M3 - Comment/debate
C2 - 35775194
AN - SCOPUS:85133220294
SN - 1078-0432
VL - 28
SP - 2969
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 13
ER -